FAP and mesothelioma: Finally, as fibrosis is a major cause of morbidity in mesothelioma patients, we investigated whether vistusertib, saracatinib and cediranib could inhibit the activation state (expression of αSMA and FAP) or the productive phenotype (expression of FN) of fibroblasts.